Bangladesh · Delayed Price · Currency is BDT Beximco Pharmaceuticals Statistics
Total Valuation
DSE:BXPHARMA has a market cap or net worth of BDT 49.92 billion. The enterprise value is 57.21 billion.
| Market Cap | 49.92B |
| Enterprise Value | 57.21B |
Important Dates
The last earnings date was Monday, November 3, 2025.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | Nov 26, 2024 |
Share Statistics
DSE:BXPHARMA has 446.11 million shares outstanding.
| Current Share Class | 446.11M |
| Shares Outstanding | 446.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.07% |
| Owned by Institutions (%) | 0.68% |
| Float | 311.68M |
Valuation Ratios
The trailing PE ratio is 7.86 and the forward PE ratio is 7.12. DSE:BXPHARMA's PEG ratio is 0.42.
| PE Ratio | 7.86 |
| Forward PE | 7.12 |
| PS Ratio | 1.08 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 12.19 |
| P/OCF Ratio | 7.53 |
| PEG Ratio | 0.42 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.40, with an EV/FCF ratio of 13.97.
| EV / Earnings | 9.00 |
| EV / Sales | 1.23 |
| EV / EBITDA | 5.40 |
| EV / EBIT | 6.50 |
| EV / FCF | 13.97 |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.13 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.58 |
| Debt / FCF | 1.51 |
| Interest Coverage | 8.48 |
Financial Efficiency
Return on equity (ROE) is 12.45% and return on invested capital (ROIC) is 9.45%.
| Return on Equity (ROE) | 12.45% |
| Return on Assets (ROA) | 7.62% |
| Return on Invested Capital (ROIC) | 9.45% |
| Return on Capital Employed (ROCE) | 14.13% |
| Revenue Per Employee | 41.30M |
| Profits Per Employee | 5.66M |
| Employee Count | 1,122 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.77 |
Taxes
In the past 12 months, DSE:BXPHARMA has paid 1.82 billion in taxes.
| Income Tax | 1.82B |
| Effective Tax Rate | 22.17% |
Stock Price Statistics
The stock price has increased by +51.22% in the last 52 weeks. The beta is 0.16, so DSE:BXPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +51.22% |
| 50-Day Moving Average | 119.57 |
| 200-Day Moving Average | 97.44 |
| Relative Strength Index (RSI) | 44.57 |
| Average Volume (20 Days) | 248,110 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:BXPHARMA had revenue of BDT 46.34 billion and earned 6.35 billion in profits. Earnings per share was 14.24.
| Revenue | 46.34B |
| Gross Profit | 20.58B |
| Operating Income | 8.80B |
| Pretax Income | 8.21B |
| Net Income | 6.35B |
| EBITDA | 10.51B |
| EBIT | 8.80B |
| Earnings Per Share (EPS) | 14.24 |
Balance Sheet
The company has 2.85 billion in cash and 6.19 billion in debt, giving a net cash position of -3.34 billion or -7.49 per share.
| Cash & Cash Equivalents | 2.85B |
| Total Debt | 6.19B |
| Net Cash | -3.34B |
| Net Cash Per Share | -7.49 |
| Equity (Book Value) | 53.63B |
| Book Value Per Share | 111.35 |
| Working Capital | 13.09B |
Cash Flow
In the last 12 months, operating cash flow was 6.63 billion and capital expenditures -2.54 billion, giving a free cash flow of 4.09 billion.
| Operating Cash Flow | 6.63B |
| Capital Expenditures | -2.54B |
| Free Cash Flow | 4.09B |
| FCF Per Share | 9.18 |
Margins
Gross margin is 44.42%, with operating and profit margins of 18.99% and 13.71%.
| Gross Margin | 44.42% |
| Operating Margin | 18.99% |
| Pretax Margin | 17.73% |
| Profit Margin | 13.71% |
| EBITDA Margin | 22.67% |
| EBIT Margin | 18.99% |
| FCF Margin | 8.84% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 3.48%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 3.48% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 24.96% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.48% |
| Earnings Yield | 12.73% |
| FCF Yield | 8.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 26, 2020. It was a forward split with a ratio of 1.1.
| Last Split Date | Nov 26, 2020 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
DSE:BXPHARMA has an Altman Z-Score of 3.32 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.32 |
| Piotroski F-Score | 7 |